EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

A randomized‐controlled trial to evaluate the app‐based multimodal weight loss program zanadio for patients with obesity

Lena Roth iD, Madeleine Ordnung, Katarina Forkmann, Nora Mehl, Annette Horstmann

Obesity · 2023-05 · 31 (5) · 1300-1310

DOI: 10.1002/oby.23744 ↗

At a glance

Randomisierte kontrollierte Studie in Obesity, published online on 2023-04-26. Written by Lena Roth and 4 co-authors. Institution: Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Major MEDLINE topics: Weight Reduction Programs, Mobile Applications. Cited 49 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

This study aimed to evaluate the effectiveness of the app‐based, multimodal weight loss program zanadio .

Methods

A randomized‐controlled trial was conducted from January 2021 to March 2022. A total of 150 adults with obesity were randomized into an intervention group and used zanadio for 1 year or into a wait list control group. The primary end point, weight change, and the secondary end points, quality of life, well‐being, and waist to height ratio, were assessed every 3 months for up to 1 year via telephone interviews and online questionnaires.

Results

After 12 months, participants of the intervention group lost, on average, −7.75% (95% CI: −9.66% to −5.84%) of their initial weight, achieving a clinically relevant and statistically stronger weight reduction than the control group (mean = 0.00% [95% CI: −1.98% to 1.99%]). All secondary end points improved significantly in the intervention group, with significantly greater improvements in well‐being and waist to height ratio than in the control group.

Conclusions

This study showed that adults with obesity who have used zanadio achieved a significant and clinically relevant weight loss within 12 months and improved further obesity‐related health variables compared with a control group. Because of its effectiveness and flexible applicability, the app‐based multimodal treatment zanadio might alleviate the present care gap for patients with obesity in Germany.

Subjects

MeSH terms (MEDLINE)

Weight Reduction ProgramsMobile ApplicationsAdultHumansQuality of LifeObesityWeight Loss

Authors and institutions

  • Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
  • aidhere GmbH, Hamburg, Germany.
  • Medical Faculty, University of Leipzig, Leipzig, Germany.

ORCID profiles: Lena Roth

Cite

APA

Roth, L., Ordnung, M., Forkmann, K., Mehl, N., & Horstmann, A. (2023). A randomized‐controlled trial to evaluate the app‐based multimodal weight loss program zanadio for patients with obesity. Obesity, 31(5), 1300-1310. https://doi.org/10.1002/oby.23744

Vancouver

Roth L, Ordnung M, Forkmann K, Mehl N, Horstmann A. A randomized‐controlled trial to evaluate the app‐based multimodal weight loss program zanadio for patients with obesity. Obesity. 2023;31(5):1300-1310. doi:10.1002/oby.23744

BibTeX
@article{Roth2023,
  author = {Roth, Lena and Ordnung, Madeleine and Forkmann, Katarina and Mehl, Nora and Horstmann, Annette},
  title = {A randomized‐controlled trial to evaluate the app‐based multimodal weight loss program zanadio for patients with obesity},
  journal = {Obesity},
  year = {2023},
  volume = {31},
  number = {5},
  pages = {1300--1310},
  doi = {10.1002/oby.23744}
}
Start for free →